Moderna(MRNA.US)盤前漲逾10% 與默沙東(MRK.US)聯手大幅降低皮膚癌復發風險
Moderna(MRNA.US)周四公布,其疫苗mRNA-4157(V940)與默沙東(MRK.US)Keytruda聯合使用顯著降低皮膚癌復發風險,死亡或癌症復發的風險降低49%。Moderna股價盤前急升逾10%,默沙東則微升0.7%。
新結果顯示,該治療方案可使III/IV期黑色素瘤患者在完全切除後復發的高風險情況下,復發或死亡風險降低49%,遠端轉移或死亡風險降低62%。相比之下,單獨使用Keytruda的效果則不如聯合使用mRNA-4157(V940)。
同時,隨訪期約為兩年的情況下,該疫苗和Keytruda將黑色素瘤患者的死亡或復發風險降低44%,並將癌症在體內擴散的風險降低65%。
兩家公司已開始對高風險黑色素瘤和非小細胞肺癌患者進行第3階段輔助研究,並計劃迅速擴展到其他腫瘤類型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.